UnitedHealth Isn’t Just Timing the Medicare Advantage Turn—Its Medical-Care Ratio Disappearing Gap Sets Up the Elevance “Peer-League” Test

Event recap → why it matters for a sector thesis

The “Medicare Advantage recovery” is becoming a peer-league: UNH’s cost signal will only be real if ELV’s next print confirms it

Investors are increasingly trading Medicare Advantage (MA) as a margin-cycle, not a single-stock story. UnitedHealth has provided an unusually testable internal signal through its Medical Care Ratio (MCR)—and its early-2026 improvement appears alongside renewed reminders of Medicare funding pressure, pricing shortfalls versus forward cost trend, and risk-adjustment model changes.

But the recovery only deserves broad “industry” credit if the next peer out of Elevance Health shows the same direction in MA medical-cost dynamics (and, crucially, doesn’t get blindsided by risk-adjustment data validation outcomes). CMS is scaling RADV audits, meaning the peer comparison is partly about what gets paid today versus what gets clawed back later.

What to watch in the next Elevance Health MA print: medical-cost trend direction (MCR/benefit expense performance), commentary on risk-adjustment/resubmission impacts, and whether any “base rate below forward trend” pressure is easing or persisting.

Falsifiable mechanism → where the margin moves actually come from

MCR is the observable battlefield: funding math (risk adjustment + rate notices) vs utilization and unit costs

Medical Care Ratio (MCR) is defined as medical costs divided by premium revenue; it compresses when pricing and/or reserves and mix improve relative to medical trend.
In UnitedHealth’s reporting, the 2025 MCR jump is explicitly tied to Medicare-related revenue effects (including Medicare funding reductions), elevated medical cost trend, and member mix changes—i.e., the “premium side” moved against them as much as the “cost side.”
In early 2026, UnitedHealth shows an MCR improvement in Q1’26 (83.9% vs 84.8% in Q1’25), but it still simultaneously expects care patterns, unit costs, and intensity of services to remain elevated—so the improvement must be doing real work, not just reflecting timing.

MCR direction check for UNH (the cleanest internal margin-cycle lens)
Period	MCR (medical costs / premium revenue)	Direction vs prior year
2023	83.2%	—
2024	85.5%	+2.3 pp
2025	89.1%	+3.6 pp
Q1 2026	83.9%	-0.9 pp vs Q1 2025

This is why the peer-league framing is useful: if “recovery” is truly structural, both UnitedHealth and Elevance Health should show comparable relief in MA medical-cost pressure (or comparable favorable reserve/risk-adjustment outcomes). If only UNH improves while ELV lags, the market should treat the turn as more company-specific or timing-driven.

Upstream policy & payment integrity → why RADV can swing peers differently

CMS risk-adjustment data validation (RADV) creates a hidden peer risk: the same coding/model issue won’t hit all plans equally

MA economics aren’t only about what providers do. They’re also about what CMS pays based on risk adjustment, and how that risk adjustment survives RADV validation. UnitedHealth’s filings explicitly flag RADV scaling and the possibility that audit outcomes could be adverse to financial results.

RADV is CMS’ risk-adjustment data validation program; it checks data submitted under risk adjustment programs and can lead to retrospective payment adjustments and other adverse outcomes.
UnitedHealth states CMS plans to substantially increase the scale and pace of RADV audits of Medicare Advantage plans.
When risk-adjustment model revisions reduce funding (especially for members with greater health and social challenges), it creates pressure that can show up as tighter premium support, benefit design constraints, and/or greater reliance on internal cost discipline.

If ELV has MA risk-adjustment resubmission or RADV-linked contingency items, near-term MCR direction may be temporarily masked—so investors should separate (1) operating cost trend from (2) payment integrity/accounting effects.

Peer setup → what ELV’s filing already hints at (before the “next reaction”)

ELV’s most telling early signal is not (yet) an MCR breakout—but the presence of Medicare Advantage risk-adjustment resubmission effects

In Elevance Health’s more recent SEC filing, the company notes (for six months ended June 30, 2026) an operating expense increase tied to a loss contingency accrual for resubmission of certain historical Medicare Advantage risk adjustment data. That is exactly the kind of payment-integrity pathway that can make “recovery” look uneven across peers.

For six months ended June 30, 2026, ELV cites an operating expense increase driven by a loss contingency accrual for resubmission of certain historical Medicare Advantage risk adjustment data.
ELV also discloses Medicare Advantage membership decreased by 15.9% (June 30, 2026: 1,897 vs June 30, 2025: 2,255; in thousands, per the filing), which can affect mix and reported trend measures.
Net: before investors assume a clean industry turn, they should treat ELV’s next print as a combined test of cost trend + risk-adjustment outcomes.

Data → what the fundamentals lens says about each peer’s “room to maneuver”

UNH has more obvious valuation “margin for error,” while ELV needs the cost/risk-adjustment story to stabilize sooner

UnitedHealth TTM revenue (approx., from dataset snapshot)

$450.1B

TTM revenue = 450129000000 (dataset snapshot dated 2026-07-23)

UnitedHealth TTM net income (approx., dataset snapshot)

$14.1B

Bottom-line net income = 14122000000 (TTM snapshot dated 2026-07-23)

Elevance Health TTM revenue (approx., dataset snapshot)

$201.1B

TTM revenue = 201113000000 (TTM snapshot dated 2026-07-23)

Elevance Health TTM net income (approx., dataset snapshot)

$5.0B

Bottom-line net income = 4963000000 (TTM snapshot dated 2026-07-23)

Valuation-style comparatives from the dataset snapshot (context, not a policy/MLR substitute)
Company	Trailing P/E (TTM snapshot)	Free cash flow yield (TTM snapshot)
UnitedHealth	31.73	6.03%
Elevance Health	16.50	7.45%

Because ELV is priced more cheaply on these snapshot multiples, the market is implicitly giving it less tolerance for a “cost/risk-adjustment” wobble. UNH’s higher multiple means the market also expects UNH’s margin improvement to persist rather than revert.

Causal chain → why UNH’s MCR improvement can be real without contradicting 2025 weakness

The UNH pattern can coexist with a broader MA slowdown: reserves/risk outcomes can flip the MCR before trend behavior changes

UNH’s 2025 MCR deterioration (to 89.1%) is explained in its filing by Medicare revenue effects and elevated medical cost trend. Yet in Q1 2026 UNH reports a lower MCR (83.9%), attributing the change to MCR mechanics including favorable reserve development and affordability/pricing actions—partially offset by expected elevated medical cost trend.

UNH in Q1’26 reports MCR decreased 0.9 pp year over year (83.9% vs 84.8%), and attributes the movement partly to favorable reserve development and affordability/pricing trends.
UNH simultaneously reiterates that care patterns, unit costs, and intensity of services are elevated and may continue—so persistent improvement requires either continued favorable reserve/risk-adjustment outcomes or structural cost discipline outpacing trend.
This frames why ELV is the key test: if cost trend is improving across the peer group, ELV should show similar directionality once it has comparable exposure to the same Medicare Advantage funding math and RADV-related payment effects.

Investor playbook → what “the next peer print” must show

If UNH’s discipline strengthens, ELV should react through reported MA medical-cost direction—not just membership or accounting noise

A monitoring checklist that converts “recovery” into falsifiable evidence
Signal	Primary filing metric to look for	Thesis implication
Medical-cost pressure	MCR / medical cost ratio / benefit expense trend commentary for MA	If improving in both peers → structural recovery more likely; if only UNH improves → UNH-specific or timing-driven recovery
Risk-adjustment uncertainty	Commentary on RADV, risk adjustment model effects, and any resubmission/contingency impacts	If ELV shows fewer or improving audit/resubmission impacts while MCR improves → recovery strengthens
Pricing vs forward trend gap	Whether management reiterates base rates below forward medical cost trend and whether mitigation is working	If gap pressure eases and pricing actions translate into margin stability → sector recovery
Reserve development behavior	Whether favorable prior-year reserve development recurs or fades	If it fades while costs remain managed → “recovery” may just be timing; if it recurs alongside cost control → more durable

Bottom line → one coherent sector thesis

UNH’s early-2026 MCR improvement is the lead indicator; ELV’s next Medicare Advantage print is the verdict on whether “recovery” is structural

The investor takeaway isn’t that Medicare Advantage is automatically recovering. It’s that the recovery story now has a measurable peer-league structure: UNH is showing MCR improvement while continuing to warn that medical trend remains elevated and Medicare funding/risk adjustment remains a headwind.

ELV’s filing already shows the kind of Medicare Advantage risk-adjustment resubmission contingency that can create uneven quarter-to-quarter results. If, after that noise, ELV still prints improving medical-cost direction comparable to UNH, investors can treat the cycle as sector-wide discipline improving. If ELV doesn’t, then UNH’s turn is more likely company- or timing-specific, and the “defensive complex” outperformance should be viewed with narrower confidence.